April E. Weisbruch focuses her practice on intellectual property matters, particularly in managing large-scale IP litigation and counseling. She works with clients in wide-ranging technology sectors, including pharmaceuticals, software applications, medical devices, organic chemistry and ballistics.
April represents clients in all phases of patent litigation, from the filing of a complaint through appeal, as well as in the highly specialized post-grant proceedings before the United States Patent Trial and Appeal Board (PTAB). She has extensive deposition, hearing and trial experience in US district courts throughout the country, as well as the US Court of Federal Claims, the US Court of Appeals for the Federal Circuit and the PTAB. Her litigation experience includes traditional ‘competitor’ litigation, litigation against non-practicing entities, ANDA litigation under the Hatch-Waxman Act and §1498 litigation against the United States of America.
April represents a wide variety of clients, including international corporations, startup companies, financial institutions and universities (as well as other academic institutions). Her focus on “full-spectrum” IP work includes complex opinion drafting as well as technology transfer, diligence and licensing work. April also has extensive experience preparing, prosecuting and obtaining both patents and trademarks for clients, as well as counseling clients on portfolio management.
April has spent several years working with colleges and universities helping numerous institutions strategically develop their intellectual property policy and portfolios. She specializes in faculty outreach, in order to help unite the academic and legal sectors to produce the best results.
While at Harvard Law School, April was a contributor to the Journal of Law and Technology. She obtained her bachelor’s degree in biochemistry at Furman University.
Secured a finding of validity of two patents for Juxtapid® on behalf of Aegerion Pharmaceuticals Inc., in response to a challenge brought by the Coalition for Affordable Drugs (Kyle Bass) at the PTAB (Coalition for Affordable Drugs VIII LLC v. Trustees of the University of Pennsylvania, IPR2015-01835 and IPR2015-01836 (PTAB))*
Obtained finding of civil contempt, and $18 million in resultant damages, relating to competitor’s purported e-procurement software ‘design-around’ sold in violation of a permanent injunction implemented after a jury trial found the patents-in-suit to be valid and infringed (ePlus Inc. v. Lawson Software, 3:09-cv-620 (E.D.Va.))*
Negotiated prompt and favorable settlement of patent troll litigation on behalf of client Essentra Components (Symbology Innovations LLC v. Essentra Components Inc., 1:19-cv-03613 (N.D.Ill.))*
Represented patent owner SecurityPoint Holdings, Inc., in §1498 litigation against The United States of America, for unauthorized use of patented technology at security screening checkpoints all major airports in the United States for over a decade (SecurityPoint Holdings, Inc. v. United States, 1:11-cv-00268 (Fed. Cl.))*
Do not send any information or documents that you want to have treated as secret or confidential. Providing information to McDermott via email links on this website or other introductory email communications will not create an attorney-client relationship; will not preclude McDermott from representing any other person or firm in any matter; and will not obligate McDermott to keep confidential the information you provide. McDermott cannot enter into an attorney-client relationship with you until McDermott has determined that doing so will not create a conflict of interest and until you and McDermott have entered into a written agreement or engagement letter that sets forth the terms of our relationship.